Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;8(6):592-599.
doi: 10.1111/1759-7714.12488. Epub 2017 Aug 30.

Overexpression of IFITM3 predicts poor prognosis in stage IIA esophageal squamous cell carcinoma after Ivor Lewis esophagectomy

Yang Jia  1 , Zhaohua Xiao  1 , Wenpeng Jiang  1 , Gang Chen  1 , Zhou Wang  1
Affiliations

Overexpression of IFITM3 predicts poor prognosis in stage IIA esophageal squamous cell carcinoma after Ivor Lewis esophagectomy

Yang Jia et al. Thorac Cancer. 2017 Nov.

Abstract

Background: Recent research has shown that IFITM3 plays an important role in the tumorigenesis of many malignancies. We investigated the clinicopathological variables and prognostic value of IFITM3 in stage IIA esophageal squamous cell carcinoma (ESCC) patients.

Methods: Immunohistochemistry and Western blot analysis were used to examine IFITM3 expression in tumor specimens. The relationships between IFITM3 expression and clinicopathological variables, as well as the five-year survival and recurrence status of patients, were analyzed.

Results: IFITM3 was aberrantly expressed in tumor tissue. Statistical analysis showed a close correlation of IFITM3 expression with T tumor status (P = 0.004). Additionally, IFITM3 overexpression, advanced T status, poor degree of differentiation, and large tumor size were not only associated with poor survival but were high lymphatic metastatic recurrence predictors in ESCC patients (P < 0.05).

Conclusion: Our data indicated that IFITM3 overexpression may predict poor prognosis in stage IIA ESCC patients after Ivor Lewis esophagectomy.

Keywords: Esophageal squamous cell carcinoma; Ivor Lewis; esophagectomy; interferon-induced transmembrane protein 3; prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunohistochemistry assay of IFITM3 in esophageal squamous cell carcinoma (ESCC) tissue and adjacent normal esophageal mucosa (ANM). (a) ANM shows no IFITM3 protein expression (×400). (b) Strong positive immunoreaction of IFITM3 in the cytoplasm of ESCC tissue (×400). (c) Moderate and (d) extremely low IFITM3 expression in ESCC tissue (×400).
Figure 2
Figure 2
Western blot analysis of IFITM3 protein expression in esophageal squamous cell carcinoma (ESCC) tissue and adjacent normal mucosa (ANM). (a) Lane 1 and 2 β‐actin protein as a control and Lane 3 and 4 IFITM3 protein expression in ESCC tissues and ANM, respectively. (b) Relative expression of IFITM3 protein in ESCC tissue and ANM.
Figure 3
Figure 3
Overall survival of stage IIA ESCC patients according to (a) IFITM3 expression level, (b) T status, (c) degree of differentiation, and (d) tumor size.
Figure 4
Figure 4
Lymphatic metastatic recurrence in stage IIA esophageal squamous cell carcinoma (ESCC) patients according to (a) IFITM3 expression level, (b) T status, (c) degree of differentiation, and (d) tumor size.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10–29. - PubMed
    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. (Published erratum appears in CA Cancer J Clin 2011; 61:134.) CA Cancer J Clin 2011; 61: 69–90. - PubMed
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917. - PubMed
    1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137–50. - PubMed
    1. Cooper JS, Guo MD, Herskovic A et al Chemoradiotherapy of locally advanced esophageal cancer: Long‐term follow‐up of a prospective randomized trial (RTOG 85‐01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623–7. - PubMed

MeSH terms

LinkOut - more resources